parenteral

Meropenem (SM 7338) is a synthetic carbapenem antibiotic with broad-spectrum antibacterial activity. It exerts a bactericidal effect by inhibiting the synthesis of peptidoglycan in the bacterial cell wall and is active against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria. Meropenem is active against both susceptible and resistant Neisseria gonorrhoeae (MIC values of 0.02–0.06 mg/mL), Haemophilus influenzae (MIC: 0.03–0.12 mg/mL), and Klebsiella pneumoniae (MIC: 0.015–0.12 mg/mL). Meropenem can be used for constructing bacterial infection models and screening for antimicrobial activity.

Meropenem trihydrate (SM 7338 trihydrate) is a carbapenem antibiotic with broad-spectrum antibacterial activity.

Norethisterone enanthate (NSC-9564) is a long-acting parenteral progestogen with antigonadotropic effects.

Cefathiamidine exhibits a wide spectrum of antimicrobial activity against bacteria. Cefathiamidine is used for the treatment of respiratory, liver, five senses, urinary tract infections, endocarditis and sepsis

Flovagatran (TGN 255) is an orally active, potent, and selective inhibitor of thrombin and parenteral direct factor II.Flovagatran is used to study venous thromboembolism.

Cinchonine (LA40221), a local anesthetic of the amide type, now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local narcotics and its parenteral use is restricted to spinal anesthesia.

Calcium glycerophosphate(CaGP) is an inhibitor of intestinal alkaline phosphatase F3. Calcium glycerophosphate can be a source of calcium and phosphorus in total parenteral nutrition solutions [1] [2].

Dexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations.

Esmolol is a cardioselective beta-blocker used in parenteral forms in the treatment of arrhythmias and severe hypertension. Esmolol has not been linked to instances of clinically apparent drug induced liver injury.

Ertapenem is a parenteral carbapenem. It has a broad spectrum of antimicrobial activity. It is highly resistant to inactivation by a wide variety of beta-lactamases.

Doripenem is a new parenteral carbapenem antibiotic with broad-spectrum activity against gram-negative and gram-positive pathogens.

Ro 09-1428, a parenteral cephalosporin, has high antipseudomonal activity.

Disodium sebacate is a 10-carbon-atom dicarboxylic acid, proposed as substrate for parenteral nutrition. It has low toxicity.

Antibacterial Agent 47 demonstrates potent antibacterial activity as an adjunct therapy to parenteral antibiotic Ceftazidime. By effectively reducing the minimum inhibitory concentration (MIC) of Ceftazidime, Antibacterial Agent 47 acts as a highly promising antimicrobial agent, thereby enhancing the overall efficacy of the treatment.

Ceftobiprole medocaril (BAL5788), the parenteral prodrug of Ceftobiprole, is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA).

Ceftobiprole medocaril sodium (BAL5788) is a parenteral prodrug of Ceftobiprole, a pyrrolidinone cephalosporin administered intravenously. As a broad-spectrum cephalosporin, Ceftobiprole exhibits high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococci (VRSA), and penicillin-resistant Streptococci. Additionally, it is effective in inhibiting both gram-positive and gram-negative pathogens.

Cefotiam (SCE-963), a parenteral cephalosporin antibiotic, exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria [1] [2].

Cefotiam dihydrochloride hydrate (SCE-963), a parenteral cephalosporin antibiotic, exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria [1] [2].

16-phenoxy tetranor PGE2, the free acid form of sulprostone, results from the hydrolysis of the methylsulfonamide bond. It is identified as a minor metabolite in human plasma following the parenteral administration of sulprostone.

Anivamersen is an RNA aptamer designed to reverse the effects of the parenteral factor IXa inhibitor pegnivacogin. REG1, a novel anticoagulation system, comprises pegnivacogin (an RNA aptamer inhibitor of coagulation factor IXa) and anivamersen (a complementary sequence reversal oligonucleotide).

Anivamersen sodium, a complementary sequence reversal oligonucleotide, serves as an RNA aptamer designed to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. Together, pegnivacogin—a coagulation factor IXa inhibiting RNA aptamer—and anivamersen comprise REG1, a novel anticoagulation system.

Sulopenem (sodium) (CP-70429 (sodium)) is an orally active, parenteral penem antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is potentially effective for treating urinary tract infections and intra-abdominal infections but is inactive against Pseudomonas aeruginosa and Xanthomonas maltophilia [1] [2] [3].

Fosciclopirox (CPX-POM), the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.

Cy5-PEG-methyltetrazine (MW 5000) is a PEG derivative utilized for modulating drug release in particulate systems designed for parenteral administration. It is applicable in research focused on drug delivery.